Journals / Van Tıp Dergisi / 2005 / Cilt: 12 - Sayı: 1

Comparison beta-2 microglobolin and other prognostic factors in Hodgkin's disease

Hodgkin hastalarında beta-2 mikroglobülinin diğer prognostik belirleyicilerle karşılaştırılması

Pages
7–11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is shown that serum p2fi level may be take place among these parameters as at least effective as others factors for reflecting tumor activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study beta-2 microglobulin (fiyi) compared was with lactat dehydrogenase (LDH), serum albumin, erythrocyte sedimentation rate (ESR) in Hodgkin's disease.
📊
Key Findings & Data:Thirty four patients (20 M, 14 F) and 19 (10 M, 9 F) healthy controls were enrolled in this study.
💡
Conclusion & Impact:It is shown that serum p2fi level may be take place among these parameters as at least effective as others factors for reflecting tumor activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Albüminler · Hodgkin hastalığı · Laktat dehidrogenazlar

Abstract

In this study beta-2 microglobulin (fiyi) compared was with lactat dehydrogenase (LDH), serum albumin, erythrocyte sedimentation rate (ESR) in Hodgkin's disease. Thirty four patients (20 M, 14 F) and 19 (10 M, 9 F) healthy controls were enrolled in this study. In the group of Hodgkin's disease (HD) before and after treatment (two times) and in the control group one time fij/i , LDH, ESR, serum albumin were assayed and compared. Mean age of the HD group was 35.0 ± 14.7 and mean age of the control group was 36.6 ± 10.0. Fifteen cases (%44.2) of the HD group were in early stage (stage I-II) and 19 cases (%55.8) were in advanced stage (stage III-IV). In the HD group, mean serum LDH level before treatment (500.6 ± 235.3) was significantly higher compared to post treatment (262.0 ± 92.7) and control groups (299.3 ± 93.2 ) (p<0.001, p=0.001 respectively). In the HD group mean' serum [12fi level before treatment (9.3 ± 9.9 ) was significantly higher compared to the post treatment '(2.2 ± 1.5 ) and the control groups (1.3 ± 0.2 ) (p<0.001, p=0.001 respectively). Mean serum albumin level before treatment (3.3 ±0.7) was significantly lower than the post treatment (3.9 ± 0.3 ) and the control groups (4.2 ± 0.3 ) (p<0.001, p<0.001 respectively). Mean serum ESR level before treatment (51.6 ± 19.7) was significantly elvated compared to the post treatment (24.2 ± 11.8) and control groups (6.3 ±3.6), (p<0.001, p=0.001 respectively). It is shown that serum p2fi level may be take place among these parameters as at least effective as others factors for reflecting tumor activity.

Özet

Amaç: Hodgkin hastalarında (HH) Beta-2 mikroglobülinin (P2p) .diğer prognostik belirleyiler olan laktatdehidrogenaz (LDH), serum albümini, eritrosit sedimantasyon hızı (ESR) ile karşılaştırılması. Yöntem: Çalışmaya 34 HH (20E, 14K) ve kontrol grubu 19 (10E, 9K) sağlıklı birey alındı. Hasta grubunda tedavi öncesi ve sonrası iki kez ve kontrol grubunda bir kez LDH, ESR, serum albiimini ve (J2fi ölçümü yapıldı. Ölçülen bu parametreler aralarında istatistiksel olarak karşılaştırıldı. Bulgular: Hasta ve kontrol grubunun yaş ortalamaları sırasıyla 35.0 ± 14.7 ve 36.6 ± 10.0 idi. Hastalarımızın 15'i (%44.2) erken evrede (Evre I-II), 19'u (%55.8) ileri evredeydi (Evre III-IV). Hastalarımızın tedavi öncesi ölçülen LDH seviyesi (U/L) (500.6 ± 235.3) tedavi sonrası (262.0 ± 92.7 ) ve kontrol grubuna (299.3 ± 93.2 ) göre anlamlı yüksek bulundu (sırasıyla, p<0.001, p=0.001). Olgularımızın tedavi öncesindeki p2u değeri (mg/L) (9.3 ± 9.9 ) tedavi sonrası (2.2 ± 1.5 ) ve kontrol grubuna (1.3 ± 0.2 ) göre anlamlı yüksek bulundu (sırasıyla, p<0.001, p=0.001). Tedavi öncesi serum albümin değeri (g/dl) (3.3 ± 0.7), tedavi sonrası (3.9 ± 0.3 ) ve kontrol grubuna (4.2 ± 0.3 ) göre istatistiksel olarak anlamlı düşük bulundu (sırasıyla, p<0.001, p<0.001). Tedavi öncesi ESR değeri (mm/sa) (51.6 ±19.7), tedavi sonrası (24.2 ± 11.8) ve kontrol grubuna (6.3 ± 3.6) göre anlamlı yüksek bulundu (sırasıyla, p<0.001,p<0r001). Sonuç: Bu hasta grubunda az çalışılmış olan p2u'in en az serum LDH, serum albümini ve ESR kadar tümör yükünü belirlemede etkin olduğu sonucuna varıldı.

🔖

Cite This Article

DEMİR, C., DİLEK, İ., ÜSTÜN, Y. (2005). Comparison beta-2 microglobolin and other prognostic factors in Hodgkin's disease. Van Tıp Dergisi, Cilt: 12 - Sayı: 1, 7–11. https://ajindex.com/articles/334250

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Diehl V, Mauch PM, Harris NL: Hodgkin’s Disease, In: DeVita VT, Hellman S, Rosenberg SA eds: Cancer Principles and Practice of Oncology. 6th Ed. Philadelphia, Pa: Lippincott Williams&Wilkins, 2339-2389, 2001
  2. Stein RS: Hodgkin’s Disease. In: Lee GR, Foerster J, Lukens J.eds: Wintrobe’s Chap 96. Clinical Hematology 10th ed. Egypt, Mass Publishing Co: 2538-2571, 1999
  3. Özdil A, Doğanay L, Demir M, Öz Puyan F, Bilgi S: Detection of Epstein-Barr Virus in Hodgkin’s Disease in Trakya Region of Turkey; by in Situ Hybridization. Turk J Haematol 19 (4): 461-464, 2002
  4. Coşkun HŞ, Eser B, Çetin M, Er Ö, Ünal A, Altınbaş M, Karahacıoğlu E, Kaplan B: Hodgkin’s Disease: Results of a Single Center in Central Anatolia, Turk J Haematol, 18 (2):117-121, 2001
  5. Kaya H, Erman Z, Gündoğdu C, Tekin SB, Gündoğdu M: Epstein-Barr Virus in Hodgkin’s Disease Patients in Northeast Anatolia. Turk J Haematol 17 (2): 61-65, 2000
  6. Brice P, Bouabdallah R, Moreau P, Divine M, Andre M, Aoudijane M, Fleury J, Anglaret B, Baruchel A, Sensebe L and Colombat P: Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Bone Marrow Transplant 20 (1): 21- 26,1997
  7. Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB and Cabanillas F: A New Serologic Staging System For Large-Cell Lymphomas Based on Initial β-2 Microglobulin and Lactate Dehydrogenase Levels. J Clin Oncol 7 (10):1518-1527, 1989
  8. Johnson AM, Rohlfs EM and Silverman LM: Proteins, In: Burtis, C.A. and Ashwood ER eds: Tietz Textbook of Clinical Chemistry. 3rd Ed. Philadelphia, Pa: W.B. Saunders Co; 477-540. 1999
  9. Moss DW and Henderson AR Clinical Enzymology, In: Burtis, C.A. and Ashwood ER eds:Tietz Textbook of Clinical Chemistry. 3rd Ed. Philadelphia,Pa:W.B. Saunders Co,1999, pp: 617- 721
  10. Straus DJ: High-Risk Hodgkin’s Disease Prognostic Factors, Leuk Lymphoma. 15:Suppl 1: 41-42, 1995
  11. Hasenclever D and Diehl V: A Prognostic Score for Advanced Hodgkin’s Disease, N Eng J Med 339 (21):1506-1514, 1998
  12. Garcia R, Hernandez JM, Caballero MD, Gonzalez M, Galende J, del Canizo MC, Vazquez L and San Miguel JF: Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer 68 (6):1227-1231,1993
  13. Hagberg H, Killander A. and Simonsson B: Serum β- 2 Microglobulin in Malignant Lymphoma. Cancer 51(12):2220-22